RU2564445C2 - Ингибиторы репликации вич - Google Patents
Ингибиторы репликации вич Download PDFInfo
- Publication number
- RU2564445C2 RU2564445C2 RU2013121788/04A RU2013121788A RU2564445C2 RU 2564445 C2 RU2564445 C2 RU 2564445C2 RU 2013121788/04 A RU2013121788/04 A RU 2013121788/04A RU 2013121788 A RU2013121788 A RU 2013121788A RU 2564445 C2 RU2564445 C2 RU 2564445C2
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- mmol
- compound
- pyridin
- added
- Prior art date
Links
- 0 CC(C)(C)OC(C(O)=O)c1c(C)nc2[s]c(CCCC3)c3c2c1-c1c[n](C(*)*)nc1 Chemical compound CC(C)(C)OC(C(O)=O)c1c(C)nc2[s]c(CCCC3)c3c2c1-c1c[n](C(*)*)nc1 0.000 description 5
- KSTKFZCVICUCSS-UHFFFAOYSA-N CC(C)(C)OC(C(O)=O)c(c(C)n1)c(-c2n[nH]cc2)c2c1[s]c1c2CCCC1 Chemical compound CC(C)(C)OC(C(O)=O)c(c(C)n1)c(-c2n[nH]cc2)c2c1[s]c1c2CCCC1 KSTKFZCVICUCSS-UHFFFAOYSA-N 0.000 description 1
- MFYZBXPPBSSWCQ-UHFFFAOYSA-N CC(C)(C)OC(C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(ccc(C)c1)c1O Chemical compound CC(C)(C)OC(C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(ccc(C)c1)c1O MFYZBXPPBSSWCQ-UHFFFAOYSA-N 0.000 description 1
- LJAJKOXCBCPBAK-UHFFFAOYSA-N CC(C)(C)OC(C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c1cc(OC)ncc1 Chemical compound CC(C)(C)OC(C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c1cc(OC)ncc1 LJAJKOXCBCPBAK-UHFFFAOYSA-N 0.000 description 1
- UVBGKMHQFWPVMK-UHFFFAOYSA-N CC(C)(C)OC(C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c1ccc2[s]c(C)nc2c1 Chemical compound CC(C)(C)OC(C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c1ccc2[s]c(C)nc2c1 UVBGKMHQFWPVMK-UHFFFAOYSA-N 0.000 description 1
- HTAGYEBKWGSDIQ-UHFFFAOYSA-N CC(C)(C)OC(C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2C1=CNC2=NC=CC2=C1 Chemical compound CC(C)(C)OC(C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2C1=CNC2=NC=CC2=C1 HTAGYEBKWGSDIQ-UHFFFAOYSA-N 0.000 description 1
- IJAYOSXMNWDRPN-HSZRJFAPSA-N CC(C)(C)O[C@@H](C(O)=O)c(c(C)nc1c2c(C(CCC3)=C)c3[s]1)c2-c(ccc(C)c1)c1O Chemical compound CC(C)(C)O[C@@H](C(O)=O)c(c(C)nc1c2c(C(CCC3)=C)c3[s]1)c2-c(ccc(C)c1)c1O IJAYOSXMNWDRPN-HSZRJFAPSA-N 0.000 description 1
- MNAQPGCEPHVVRF-OGDGHAERSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)n1)c2-c(ccc(Cl)c3)c3OCC(CCC3)c4c3[s]c1c24 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)n1)c2-c(ccc(Cl)c3)c3OCC(CCC3)c4c3[s]c1c24 MNAQPGCEPHVVRF-OGDGHAERSA-N 0.000 description 1
- HXXYHUUEZMENOP-NRFANRHFSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(cc1)ccc1Cl Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(cc1)ccc1Cl HXXYHUUEZMENOP-NRFANRHFSA-N 0.000 description 1
- RXKUZMGPMATVJK-QFIPXVFZSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(ccc(C)c1)c1F Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(ccc(C)c1)c1F RXKUZMGPMATVJK-QFIPXVFZSA-N 0.000 description 1
- MFYZBXPPBSSWCQ-QFIPXVFZSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(ccc(C)c1)c1O Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(ccc(C)c1)c1O MFYZBXPPBSSWCQ-QFIPXVFZSA-N 0.000 description 1
- YDNFRXQQXLZQGV-NRFANRHFSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(cccc1)c1O Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(cccc1)c1O YDNFRXQQXLZQGV-NRFANRHFSA-N 0.000 description 1
- FTQISHKCVRYCHE-NRFANRHFSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c1ccc(C(F)(F)F)cc1 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c1ccc(C(F)(F)F)cc1 FTQISHKCVRYCHE-NRFANRHFSA-N 0.000 description 1
- NJNANSPFHGTFSE-IBGZPJMESA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c1cncnc1 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c1cncnc1 NJNANSPFHGTFSE-IBGZPJMESA-N 0.000 description 1
- VRNIORWEWKHCCR-WFHLNLCJSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2C1=CC2SC(C)=NC2C=C1 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2C1=CC2SC(C)=NC2C=C1 VRNIORWEWKHCCR-WFHLNLCJSA-N 0.000 description 1
- GBZIZRJYQYIXMU-XLDIYJRPSA-N CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2C1=C[NH+]2[N-]C=CC2C=C1 Chemical compound CC(C)(C)O[C@H](C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2C1=C[NH+]2[N-]C=CC2C=C1 GBZIZRJYQYIXMU-XLDIYJRPSA-N 0.000 description 1
- NXUFMBBZIOWMGR-UHFFFAOYSA-N CC(C)(C)[O-2]C(C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(cc1)ccc1Br Chemical compound CC(C)(C)[O-2]C(C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(cc1)ccc1Br NXUFMBBZIOWMGR-UHFFFAOYSA-N 0.000 description 1
- YVRCVPCCDBGTBR-UHFFFAOYSA-N CC(C)(C)[O-2]c1cc(C#N)ncc1-c1c(CC(O)=O)c(C)nc2c1c(CCCC1)c1[s]2 Chemical compound CC(C)(C)[O-2]c1cc(C#N)ncc1-c1c(CC(O)=O)c(C)nc2c1c(CCCC1)c1[s]2 YVRCVPCCDBGTBR-UHFFFAOYSA-N 0.000 description 1
- XRALHHGMTITDCU-UHFFFAOYSA-N CC(C)(C)[O-2]c1nc(OC)ncc1-c1c(CC(O)=O)c(C)nc2c1c(CCCC1)c1[s]2 Chemical compound CC(C)(C)[O-2]c1nc(OC)ncc1-c1c(CC(O)=O)c(C)nc2c1c(CCCC1)c1[s]2 XRALHHGMTITDCU-UHFFFAOYSA-N 0.000 description 1
- FPUUWMIOQNYGMP-UHFFFAOYSA-N CC(C)(C)[O-]C(C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(ccc(Cl)c1)c1F Chemical compound CC(C)(C)[O-]C(C(O)=O)c(c(C)nc1c2c(CCCC3)c3[s]1)c2-c(ccc(Cl)c1)c1F FPUUWMIOQNYGMP-UHFFFAOYSA-N 0.000 description 1
- AQGQGZICGWHKGX-UHFFFAOYSA-N CC(C)([O-4])OC(Cc(c(C)n1)c2-c(ccc(C)c3)c3OCC(CCC3)c4c3[s]c1c24)=O Chemical compound CC(C)([O-4])OC(Cc(c(C)n1)c2-c(ccc(C)c3)c3OCC(CCC3)c4c3[s]c1c24)=O AQGQGZICGWHKGX-UHFFFAOYSA-N 0.000 description 1
- DSPKIWRTNYJDMH-QVCARPALSA-N CC/C(/C=C/O)=C/C=C/c1c([C@@H](C(O)=O)OC(C)(C)C)c(C)nc2c1c(CCCC1)c1[s]2 Chemical compound CC/C(/C=C/O)=C/C=C/c1c([C@@H](C(O)=O)OC(C)(C)C)c(C)nc2c1c(CCCC1)c1[s]2 DSPKIWRTNYJDMH-QVCARPALSA-N 0.000 description 1
- BISXMNULWGKNJK-NRFANRHFSA-N CCO[C@H](C(O)=O)c1c(C)nc2[s]c(CCCC3)c3c2c1-c1c(CO)cccc1 Chemical compound CCO[C@H](C(O)=O)c1c(C)nc2[s]c(CCCC3)c3c2c1-c1c(CO)cccc1 BISXMNULWGKNJK-NRFANRHFSA-N 0.000 description 1
- SLYVDHVWFXCFGB-UHFFFAOYSA-N Cc(cc1)ccc1-c1c(CC(O)=O)c(C)nc2c1c(CCOC1)c1[s]2 Chemical compound Cc(cc1)ccc1-c1c(CC(O)=O)c(C)nc2c1c(CCOC1)c1[s]2 SLYVDHVWFXCFGB-UHFFFAOYSA-N 0.000 description 1
- MXXQOTRKRPIVPL-UHFFFAOYSA-N Cc1nc([s]c2c3CCCC2)c3c(-c2ccc(C(F)F)cc2)c1CC(O)=O Chemical compound Cc1nc([s]c2c3CCCC2)c3c(-c2ccc(C(F)F)cc2)c1CC(O)=O MXXQOTRKRPIVPL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41361810P | 2010-11-15 | 2010-11-15 | |
| US61/413,618 | 2010-11-15 | ||
| US201161485355P | 2011-05-12 | 2011-05-12 | |
| US61/485,355 | 2011-05-12 | ||
| PCT/IB2011/054852 WO2012066442A1 (en) | 2010-11-15 | 2011-11-01 | Inhibitors of hiv replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013121788A RU2013121788A (ru) | 2014-12-27 |
| RU2564445C2 true RU2564445C2 (ru) | 2015-10-10 |
Family
ID=44999830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013121788/04A RU2564445C2 (ru) | 2010-11-15 | 2011-11-01 | Ингибиторы репликации вич |
Country Status (15)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| US9102614B2 (en) | 2010-07-02 | 2015-08-11 | Gilead Sciences, Inc. | Naphth-2-ylacetic acid derivatives to treat AIDS |
| JP5806735B2 (ja) | 2010-07-02 | 2015-11-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ抗ウイルス化合物としての２−キノリニル−酢酸誘導体 |
| AU2011331301A1 (en) | 2010-11-15 | 2013-05-23 | Katholieke Universiteit Leuven | Antiviral condensed heterocyclic compounds |
| WO2012066442A1 (en) * | 2010-11-15 | 2012-05-24 | Pfizer Limited | Inhibitors of hiv replication |
| AP2015008931A0 (en) | 2011-04-21 | 2015-12-31 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
| JP6099149B2 (ja) | 2011-10-25 | 2017-03-22 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害剤 |
| WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
| US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
| UY34750A (es) | 2012-04-20 | 2013-11-29 | Gilead Sciences Inc | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. |
| US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| TW201441197A (zh) | 2013-01-31 | 2014-11-01 | Shionogi & Co | Ｈｉｖ複製抑制劑 |
| US9580431B2 (en) | 2013-03-13 | 2017-02-28 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP2970273B1 (en) | 2013-03-13 | 2017-03-01 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP2970301B1 (en) | 2013-03-13 | 2017-01-11 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| ES2623904T3 (es) | 2013-03-14 | 2017-07-12 | VIIV Healthcare UK (No.5) Limited | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| WO2014159076A1 (en) | 2013-03-14 | 2014-10-02 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| CN105473573B (zh) | 2013-06-25 | 2018-03-16 | 百时美施贵宝公司 | 用作激酶抑制剂的咔唑甲酰胺化合物 |
| TWI648272B (zh) | 2013-06-25 | 2019-01-21 | 美商必治妥美雅史谷比公司 | 經取代之四氫咔唑及咔唑甲醯胺化合物 |
| EP2821082A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use |
| EP3105236B1 (en) | 2014-02-12 | 2017-10-18 | ViiV Healthcare UK (No.5) Limited | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| US9409922B2 (en) | 2014-02-18 | 2016-08-09 | Bristol-Myers Squibb Company | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
| US9932353B2 (en) | 2014-02-18 | 2018-04-03 | Viiv Healthcare Uk (No. 5) Limited | Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| WO2015126743A1 (en) | 2014-02-18 | 2015-08-27 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| US9273067B2 (en) | 2014-02-19 | 2016-03-01 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
| PT3107913T (pt) | 2014-02-19 | 2018-09-28 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| JP6579549B2 (ja) | 2014-05-16 | 2019-09-25 | 塩野義製薬株式会社 | Ｈｉｖ複製阻害作用を有する３環性複素環誘導体 |
| AU2015335783B2 (en) | 2014-10-24 | 2019-10-03 | Bristol-Myers Squibb Company | Tricyclic atropisomer compounds |
| SI3461821T1 (sl) | 2014-10-24 | 2020-09-30 | Bristol-Myers Squibb Company | Spojine indol karboksamida, uporabne kot kinazni inhibitorji |
| TN2017000158A1 (en) | 2014-10-24 | 2018-10-19 | Bristol Myers Squibb Co | Carbazole derivatives |
| WO2016180770A1 (en) * | 2015-05-08 | 2016-11-17 | Katholieke Universiteit Leuven | Functional cure of retroviral infection |
| CN107922423B (zh) | 2015-05-29 | 2020-10-27 | 盐野义制药株式会社 | 具有hiv复制抑制作用的含氮三环性衍生物 |
| CN111018912A (zh) * | 2019-11-22 | 2020-04-17 | 苏州二叶制药有限公司 | 一种抗病毒药物关键中间体的合成和纯化方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2144033C1 (ru) * | 1994-03-07 | 2000-01-10 | Варнер-Ламберт Компани | Производные бензотиофена, бензофурана, индолтиазепинона, оксазепинона и диазепинона, фармацевтическая композиция, обладающая ингибирующей клеточную адгезию или вич-активностью, способ торможения адгезии лейкоцитов к эндотелиальным клеткам при лечении вызванных ею болезней, способ лечения млекопитающих, зараженных вич |
| WO2005076861A2 (en) * | 2004-02-04 | 2005-08-25 | University Of Virginia Patent Foundation | Compounds that inhibit hiv particle formation |
| RU2008137929A (ru) * | 2008-09-24 | 2010-03-27 | Александр Леонидович Гинцбург (RU) | Биологически активные вещества, подавляющие патогенные бактерии и способ их получения |
| WO2010130842A1 (en) * | 2009-05-15 | 2010-11-18 | Katholieke Universiteit Leuven | Thieno [2, 3-b] pyridine derivatives as viral replication inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US7112594B2 (en) * | 2000-08-09 | 2006-09-26 | Mitsubishi Pharma Corporation | Fused bicyclic amide compounds and medicinal use thereof |
| JP2003171381A (ja) | 2001-09-25 | 2003-06-20 | Takeda Chem Ind Ltd | エントリー阻害剤 |
| JP2003119137A (ja) | 2001-10-10 | 2003-04-23 | Japan Tobacco Inc | Ｈｉｖ阻害剤 |
| DE60218511T2 (de) | 2001-10-26 | 2007-10-25 | Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| AU2002349675A1 (en) | 2001-12-05 | 2003-06-17 | Shionogi And Co., Ltd. | Derivative having hiv integrase inhibitory activity |
| JP2005515206A (ja) | 2001-12-12 | 2005-05-26 | ブリストル−マイヤーズ スクイブ カンパニー | Ｈｉｖインテグラーゼ・インヒビター |
| BR0215260A (pt) | 2001-12-21 | 2004-12-07 | Tibotec Pharm Ltd | Inibidores de hiv protease de sulfonamida contendo fenila substituìda heterocìclica de amplo espectro |
| JP4523281B2 (ja) | 2002-01-17 | 2010-08-11 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｈｉｖインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類 |
| TW200306192A (en) | 2002-01-18 | 2003-11-16 | Bristol Myers Squibb Co | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors |
| BRPI0519521A2 (pt) * | 2004-12-17 | 2009-02-10 | Hoffmann La Roche | derivados de tieno-piridina como aumentadores alostÉricos gaba-b |
| RU2503679C2 (ru) * | 2007-11-15 | 2014-01-10 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| AU2010334958B2 (en) | 2009-12-23 | 2015-02-05 | Katholieke Universiteit Leuven | Novel antiviral compounds |
| AU2011331301A1 (en) | 2010-11-15 | 2013-05-23 | Katholieke Universiteit Leuven | Antiviral condensed heterocyclic compounds |
| WO2012066442A1 (en) * | 2010-11-15 | 2012-05-24 | Pfizer Limited | Inhibitors of hiv replication |
| WO2012102985A1 (en) | 2011-01-24 | 2012-08-02 | Glaxosmithkline Llc | Isoquinoline compounds and methods for treating hiv |
| EP2731436B1 (en) | 2011-07-15 | 2017-03-08 | VIIV Healthcare UK Limited | 2-(pyrrolo[2,3-b]pyridine-5-yl)-2-(t-butoxy)-acetic acid derivatives as hiv replication inhibitors for the treatment of aids |
-
2011
- 2011-11-01 WO PCT/IB2011/054852 patent/WO2012066442A1/en active Application Filing
- 2011-11-01 AU AU2011330850A patent/AU2011330850B2/en not_active Ceased
- 2011-11-01 RU RU2013121788/04A patent/RU2564445C2/ru not_active IP Right Cessation
- 2011-11-01 MX MX2013005486A patent/MX343274B/es active IP Right Grant
- 2011-11-01 CA CA2817896A patent/CA2817896A1/en not_active Abandoned
- 2011-11-01 BR BR112013011991A patent/BR112013011991A2/pt not_active IP Right Cessation
- 2011-11-01 CN CN201180065030.5A patent/CN103429595B/zh not_active Expired - Fee Related
- 2011-11-01 EP EP11785122.0A patent/EP2640729B1/en active Active
- 2011-11-01 CN CN201510602538.4A patent/CN105330675A/zh active Pending
- 2011-11-01 JP JP2013538301A patent/JP5902704B2/ja not_active Expired - Fee Related
- 2011-11-10 TW TW100141049A patent/TWI445709B/zh not_active IP Right Cessation
- 2011-11-14 UY UY0001033729A patent/UY33729A/es not_active Application Discontinuation
- 2011-11-14 US US13/295,167 patent/US8809363B2/en not_active Expired - Fee Related
- 2011-11-14 AR ARP110104246A patent/AR083870A1/es unknown
-
2013
- 2013-05-10 ZA ZA2013/03433A patent/ZA201303433B/en unknown
- 2013-05-14 CL CL2013001338A patent/CL2013001338A1/es unknown
-
2014
- 2014-07-02 US US14/322,134 patent/US9447116B2/en not_active Expired - Fee Related
-
2016
- 2016-03-10 JP JP2016046384A patent/JP2016164163A/ja active Pending
- 2016-04-22 AU AU2016202565A patent/AU2016202565A1/en not_active Abandoned
- 2016-08-19 US US15/241,520 patent/US20160355528A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2144033C1 (ru) * | 1994-03-07 | 2000-01-10 | Варнер-Ламберт Компани | Производные бензотиофена, бензофурана, индолтиазепинона, оксазепинона и диазепинона, фармацевтическая композиция, обладающая ингибирующей клеточную адгезию или вич-активностью, способ торможения адгезии лейкоцитов к эндотелиальным клеткам при лечении вызванных ею болезней, способ лечения млекопитающих, зараженных вич |
| WO2005076861A2 (en) * | 2004-02-04 | 2005-08-25 | University Of Virginia Patent Foundation | Compounds that inhibit hiv particle formation |
| RU2008137929A (ru) * | 2008-09-24 | 2010-03-27 | Александр Леонидович Гинцбург (RU) | Биологически активные вещества, подавляющие патогенные бактерии и способ их получения |
| WO2010130842A1 (en) * | 2009-05-15 | 2010-11-18 | Katholieke Universiteit Leuven | Thieno [2, 3-b] pyridine derivatives as viral replication inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103429595B (zh) | 2015-10-21 |
| ZA201303433B (en) | 2014-12-23 |
| TW201300395A (zh) | 2013-01-01 |
| EP2640729A1 (en) | 2013-09-25 |
| CA2817896A1 (en) | 2012-05-24 |
| MX2013005486A (es) | 2013-12-12 |
| CN103429595A (zh) | 2013-12-04 |
| AU2016202565A1 (en) | 2016-05-19 |
| AU2011330850B2 (en) | 2016-01-28 |
| EP2640729B1 (en) | 2016-12-21 |
| US8809363B2 (en) | 2014-08-19 |
| JP2013542247A (ja) | 2013-11-21 |
| TWI445709B (zh) | 2014-07-21 |
| CL2013001338A1 (es) | 2014-03-28 |
| US9447116B2 (en) | 2016-09-20 |
| WO2012066442A1 (en) | 2012-05-24 |
| RU2013121788A (ru) | 2014-12-27 |
| CN105330675A (zh) | 2016-02-17 |
| JP2016164163A (ja) | 2016-09-08 |
| US20140315927A1 (en) | 2014-10-23 |
| AU2011330850A1 (en) | 2013-06-27 |
| JP5902704B2 (ja) | 2016-04-13 |
| MX343274B (es) | 2016-10-31 |
| UY33729A (es) | 2012-06-29 |
| US20160355528A1 (en) | 2016-12-08 |
| US20120136023A1 (en) | 2012-05-31 |
| BR112013011991A2 (pt) | 2016-08-30 |
| AR083870A1 (es) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2564445C2 (ru) | Ингибиторы репликации вич | |
| KR101483834B1 (ko) | 항바이러스 화합물 | |
| JP5925394B2 (ja) | 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体 | |
| US9132129B2 (en) | Antiviral compounds | |
| AU2014205315B2 (en) | Therapeutic compounds for the treatment of viral infections | |
| US9096586B2 (en) | Therapeutic compounds | |
| JP5372751B2 (ja) | Ａｚａ−ペプチドプロテアーゼ阻害剤 | |
| US20130078256A1 (en) | Novel hiv reverse transcriptase inhibitors | |
| US20140296266A1 (en) | Therapeutic compounds | |
| US20160272635A1 (en) | Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases | |
| ES2574831T3 (es) | Inhibidores de la proteasa antivirales | |
| JP2006225388A (ja) | ピペラジン誘導体 | |
| WO2006085199A1 (en) | Piperazine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20181102 |